Results 121 to 130 of about 59,251 (307)

Pharmacologic approaches against advanced glycation end products (ages) in diabetic cardiovascular disease [PDF]

, 2015
Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients.
Avtaar Singh, Sanjeet Singh, Chello, Massimo, DI DOMENICO, Fabio, Nappi, Francesco, Nenna, Antonio, Spadaccio, Cristiano, Sutherland, Fraser W   +6 more
core   +2 more sources

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Sacubitril/valsartan and isolated systolic hypertension in elderly patients: a prospective study

Известия высших учебных заведений. Поволжский регион: Медицинские науки
Background. The purpose of the research is to evaluate the antihypertensive efficacy of sacubitril/valsartan 200 mg/day compared with valsartan 160 mg/day in patients with grade 1–2 isolated systolic arterial hypertension (ISAH).
A.S. Ryazanov, M.V. Makarovskaya, N.A. Anisimov, L.V. Melnikova   +3 more
doaj   +1 more source

Is early and fast blood pressure control important in hypertension management? [PDF]

, 2018
Control of blood pressure (BP) in hypertension is recognized as a key measure in the management of cardiovascular (CV) risk and is a cornerstone of preventive strategies. It is not defined, however, whether an initiation of the antihypertensive treatment
Gallo, Giovanna, Tocci, Giuliano, Volpe, Massimo   +2 more
core   +1 more source

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

Lipids in Health and Disease
Background and objective Dyslipidemia is significantly more common in those with concurrent chronic kidney disease (CKD) and chronic heart failure (CHF).
Manzhi Li, Ao Zhong, Yifan Tang, Jinnuo Yu, Mengmeng Wu, Karthick Kumaran Munisamy Selvam, Dong Sun   +6 more
doaj   +1 more source

Review Article : Sacubitril/valsartan use for the hospitalist [PDF]

, 2017
The mainstays of therapy for heart failure with reduced ejection fraction (HFrEF) have traditionally been angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), beta-blockers, aldosterone receptor antagonists, and ...
Hart, James, Littrell, Rachel, Padkins, Mitchell   +2 more
core   +1 more source

Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials [PDF]

, 2022
Hong-Xing Wu, Keke Liu, Bo‐Ning Li, Sha Liu, Jingchun Jin   +4 more
openalex   +1 more source

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)

Scientific Reports
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and
Ning Wang, Haijun Wang, Ying Chen, Yanfeng Wang   +3 more
doaj   +1 more source

Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma [PDF]

, 2002
No abstract ...
Bray, C.A., Hole, D.J., Mackie, R.M.
core   +2 more sources